Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Cancer Immunology, Immunotherapy : CII|February 7, 2022
Adoptive cell therapies in thoracic malignanciesJulie Lasvergnas, Marie Naigeon, Kader Chouahnia, et al.
Cancer Treatment Reviews|April 26, 2022
The use of immunotherapy in older patients with advanced non-small cell lung cancerMarco Tagliamento, Maxime Frelaut, Capucine Baldini, et al.
RMD Open|May 20, 2026
PD1<sup>+</sup> TIGIT<sup>+</sup> CD4<sup>+</sup> T cells predict response to anti-TNF in rheumatoid arthritis and spondyloarthritisSamuel Bitoun, Matthieu Roulleaux-Dugage, Marie Naigeon, et al.
Translational Lung Cancer Research|July 23, 2021
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancerBoris Duchemann, Jordi Remon, Marie Naigeon, et al.
Clinical and Experimental Immunology|September 8, 2025
Expanded senescent CD8 T cells in IMID patients are associated with distinct inflammatory cytokinesMarie Naigeon, Samuel Bitoun, Matthieu Roulleaux Dugage, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2024
Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trialsEdouard Auclin, Matthieu Roulleaux Dugage, Teresa Gorria, et al.
Cancers|December 8, 2020
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung CancerBoris Duchemann, Jordi Remon, Marie Naigeon, et al.
Exploration of Targeted Anti-Tumor Therapy|October 28, 2024
Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinomaLoubna Omri, Marie Naigeon, Ronan Flippot, et al.
Lung Cancer (Amsterdam, Netherlands)|December 26, 2021
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trialMariona Riudavets, Marie Naigeon, Matthieu Texier, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockersBoris Duchemann, Marie Naigeon, Edouard Auclin, et al.
Pageof 3